Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
Podcast: Giredestrant Promising New Treatment For Early-Stage HR-Positive Breast Cancer
moderators
Posts: 9,773
Giredestrant Promising New Treatment For Early-Stage HR-Positive Breast Cancer
December 10, 2025
After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:
- how giredestrant is different from the two other available SERDs
- if giredestrant could be combined with a CDK4/6 inhibitor
- giredestrant side effects
- what the results mean for people diagnosed with early-stage hormone receptor-positive breast cancer
Tagged:
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.